
18 Nov SAHPRA Shares South Africa’s Patient-Focused Approach at the ICMRA Summit 2026 in Seoul
Pretoria, 18 November 2026 – The South African Health Products Regulatory Authority (SAHPRA) took part in the International Coalition of Medicines Regulatory Authorities (ICMRA) Summit 2026, held at the Conrad Seoul in the Republic of Korea. SAHPRA’s Chief Executive Officer, Dr Boitumelo Semete-Makokotlela, presented in Session 3 of the Summit on 4 November 2026. She spoke on how South Africa is working to place patients at the centre of drug development and to strengthen the regulatory frameworks that protect them.
SAHPRA’s participation is part of the Authority’s ongoing commitment to international regulatory collaboration. This article summarises the Summit, SAHPRA’s contribution and what it means for South African patients, researchers, industry and other stakeholders.
About ICMRA and the 2026 Summit
ICMRA is a voluntary, executive-level body of medicines regulatory authorities that works together to address current and emerging regulatory and safety challenges for human medicines. It provides direction on areas common to many regulators, identifies opportunities for collaboration and supports communication, information sharing and crisis response worldwide.
The 2026 ICMRA Summit and Plenary took place from 3 to 6 November 2026 at the Conrad Seoul. It was hosted by the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea, and brought together the heads and senior leaders of medicines regulators from across the globe. The week included bilateral meetings, an Executive Committee meeting, the one-day Summit on 4 November and the ICMRA Plenary on 5 November.
Heads of medicines regulators from around 30 countries attended, including the European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). ICMRA brings together 43 regulatory agencies from 40 member countries, together with the World Health Organization. The Seoul meeting was the first held in Korea since the country became a founding member in 2013. It came shortly after Korea’s Ministry of Food and Drug Safety was elected to the ICMRA Executive Committee for the 2026–2029 term.
Session 1: Artificial intelligence in medicines regulation
The first session looked at how regulators can govern and use AI responsibly. It was co-chaired by Korea’s MFDS and Singapore’s Health Sciences Authority (HSA), and it doubled as the International Artificial Intelligence Regulatory Industry Symposium (AIRIS) 2026. Presentations came from the US Food and Drug Administration (FDA), the EMA, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), Spain’s AEMPS, Saudi Arabia’s SFDA and Brazil’s ANVISA.
Session 2: New approach methodologies and the 3Rs
The second session addressed the shift from traditional animal testing to new approach methodologies (NAMs), such as AI-based models and organoids (miniature lab-grown organs). This shift is driven by the limits of animal models in predicting human outcomes and by growing ethical expectations. The session aimed to:
- establish a shared conceptual framework for classifying NAMs and discuss how to achieve global regulatory harmonisation;
- share the background and long-term goals of the ICMRA statement on the 3Rs (Replacement, Reduction and Refinement) of animal testing, published on 1 October 2026; and
- identify where regulators can engage, drawing on real-world use cases from leading authorities.
Presenters came from the Netherlands (MEB), Canada, Switzerland, Chinese Taipei, the EMA, the US FDA and China’s NMPA.
Session 3: Patient-focused drug development
The final session explored how regulators can bring the patient perspective into drug development and strengthen their own frameworks. It was co-chaired by Poland’s Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) and the EMA. Presentations came from the MHRA, Swissmedic, SAHPRA, Australia’s TGA, the US FDA, HSA, NMPA and the European Commission’s DG SANTE with the EMA and URPL, followed by a panel discussion. The Summit closed with remarks from the ICMRA Chair at 16:15, and delegates joined a gala dinner that evening.
SAHPRA’s participation strengthens South Africa’s voice in global regulatory discussions and creates opportunities to learn from, and contribute to, international good practice.
Looking Ahead
The Seoul Summit reinforced that the world’s regulators face shared challenges, from the rise of AI to the move away from animal testing and the need to put patients at the centre of regulation. SAHPRA will continue to engage with ICMRA and its members, apply the lessons from Seoul to strengthen patient involvement in South Africa, and keep stakeholders informed as this work progresses.
To learn more about ICMRA, visit www.icmra.info.